NASDAQ: AKTSAktis Oncology Inc Stock
$22.40
Updated Jan 9, 2026
AKTS Price
$22.40
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$19.33
52 Week High
$29.16
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.59
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AKTS Overview
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKTS's potential to beat the market
- AKTS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKTS
RankedUnranked of 490
RankedUnranked of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.71 | A | |
| $161.13 | A | |
| $6.10 | A |
Be the first to know about important AKTS news, forecast changes, insider trades & much more!
AKTS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTS's short-term assets ($249.42M) exceed its short-term liabilities ($26.91M)
Short-term Liabilities Financials
AKTS's short-term assets ($249.42M) exceed its long-term liabilities ($51.11M)
Long-term Liabilities Financials
AKTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more AKTS due diligence checks available for Premium users.
Valuation
AKTS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$279.0M
Liabilities
$78.0M
Debt to equity
-0.59
AKTS's short-term assets ($249.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTS's short-term assets ($249.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Aktis Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.